Adjuvant Chemotherapy and Follow-Up

  • Francesco Leone


Even though there are no definitive data supporting the use of adjuvant chemotherapy after liver resection for initially resectable hepatic colorectal metastases, the rationale for this approach seems evident. The activity of chemotherapy in metastatic disease is well known, and it is broadly accepted that, at least theoretically, patients with micrometastatic disease after radical surgery will benefit from systemic chemotherapy, as will patients undergoing surgery for stage III colon cancer.


Adjuvant Chemotherapy Clin Oncol Liver Resection Colorectal Liver Metastasis Folinic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939–944CrossRefGoogle Scholar
  2. 2.
    Goldberg RM, Hatfield AK, Kahn M et al (1997) Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 15:3320–3329PubMedGoogle Scholar
  3. 3.
    Moertel CG, Fleming TR, Macdonald JS et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326PubMedGoogle Scholar
  4. 4.
    Wolmark N, Rockette H, Fisher B et al (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879–1887PubMedGoogle Scholar
  5. 5.
    Mamounas E, Wieand S, Wolmark N et al (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349–55PubMedGoogle Scholar
  6. 6.
    Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. (1999) J Clin Oncol 17:1356–63Google Scholar
  7. 7.
    Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351CrossRefPubMedGoogle Scholar
  8. 8.
    Wolmark N, Kuebler JP, Colangelo L et al (2005) A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc Amer Soc Clin Oncol (abstr # 3500)Google Scholar
  9. 9.
    Sargent DJ, Wieand HS, Haller DG et al (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664–8670CrossRefPubMedGoogle Scholar
  10. 10.
    Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer (X-ACT Trial). N Engl J Med 352:2696–2704CrossRefPubMedGoogle Scholar
  11. 11.
    Scheithauer W, McKendrick J, Begbie et al (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 14:1735–1743CrossRefPubMedGoogle Scholar
  12. 12.
    Haller D, Tabernero J, Maroun J et al (2009) First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). Joint ECCO 15–34th ESMO Multidisciplinary Congress. Abstract #5LBAGoogle Scholar
  13. 13.
    Parks R, Gonen M, Kemeny N et al (2007) Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 204:753–761CrossRefPubMedGoogle Scholar
  14. 14.
    Fong Y, Fortner JG, Sun R et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–321CrossRefPubMedGoogle Scholar
  15. 15.
    Lygidakis NJ, Ziras N, Parissis J (1995) Resection versus resection combined with adjuvant pre-and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 42:155–161PubMedGoogle Scholar
  16. 16.
    Asahara T, Kikkawa M, Okajima M et al (1998) Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepatogastroenterology 45:805–811PubMedGoogle Scholar
  17. 17.
    Lorenz M, Müller HH, Schramm H et al (1998) Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer: German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228:756–762CrossRefPubMedGoogle Scholar
  18. 18.
    Kemeny MM, Adak S, Gray B et al (2002) Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an Intergroup study. J Clin Oncol 20:1499–1505CrossRefPubMedGoogle Scholar
  19. 19.
    Tono T, Hasuike Y, Ohzato H et al (2000) Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study. Cancer 88:1549–1556CrossRefPubMedGoogle Scholar
  20. 20.
    Lygidakis NJ, Sgourakis G, Vlachos L et al (2001) Metastatic liver disease of colorectal origin: The value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection: Results of a prospective randomized study. Hepatogastroenterology 48:1685–1691PubMedGoogle Scholar
  21. 21.
    Kemeny N, Huang Y, Cohen AM et al (1999) Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039–2048CrossRefPubMedGoogle Scholar
  22. 22.
    Kemeny NE, Gonen M (2005) Hepatic arterial infusion after liver resection. N Engl J Med 352:734–735CrossRefPubMedGoogle Scholar
  23. 23.
    Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976–4982CrossRefPubMedGoogle Scholar
  24. 24.
    Langer B, Bleiberg H, Labianca R et al (2002) Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): Results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. J Clin Oncol 21(abstr 592)Google Scholar
  25. 25.
    Mitry E, Fields A, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. J Clin Oncol 26:4906–4911CrossRefPubMedGoogle Scholar
  26. 26.
    Ychoul M, Hohenberger W, Thezenas S et al (2009) A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20:1964–1970CrossRefGoogle Scholar
  27. 27.
    Power DG, Kemeny NE (2010) Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol 28:2300–2309CrossRefPubMedGoogle Scholar
  28. 28.
    Muratore A, Polastri R, Bouzari H et al (2001) Repeat hepatectomy for colorectal liver metastases: a worthwhile operation? J Surg Oncol 76:127–132CrossRefPubMedGoogle Scholar
  29. 29.
    Petrowsky H, Gonen M, Jarnagin W et al (2002) Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 235:863–871CrossRefPubMedGoogle Scholar
  30. 30.
    Adam R, Pascal G, Azoulay D et al (2003) Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 238:871–884CrossRefPubMedGoogle Scholar
  31. 31.
    Saito Y, Omiya H, Kohno K et al (2002) Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 124:1007–1013CrossRefPubMedGoogle Scholar
  32. 32.
    Secco GB, Fardelli R, Gianquinto D et al (2002) Efficacy and cost of risk adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 28:418–423CrossRefPubMedGoogle Scholar
  33. 33.
    Rodriguez-Moranta F, Salo J, Arcusa A et al (2005) Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: A prospective, multicenter, randomized, controlled trial. J Clin Oncol 24:1–8Google Scholar
  34. 34.
    Figueredo A, Rumble RB, Maroun J et al (2003) Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario’s. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 3:26CrossRefPubMedGoogle Scholar
  35. 35.
    Tjandra JJ, Chan MK (2007) Follow-up after curative resection of colorectal cancer: a metaanalysis. Dis Col Rect 50:1783–1799CrossRefGoogle Scholar
  36. 36.
    Desch CE, Benson III AB, Somerfield MR et al (2005) Colorectal Cancer Surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 23:8512–8519CrossRefPubMedGoogle Scholar
  37. 37.
    Tsikitis VL, Malireddy K, Green EA et al (2009) Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol 27:3671–3676CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2011

Authors and Affiliations

  • Francesco Leone
    • 1
  1. 1.Division of Medical OncologyInstitute for Cancer Research and TreatmentCandiolo (TO)Italy

Personalised recommendations